Validation of HPLC-UV methods for quantitatively determining landiolol and its major metabolite in human blood

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 1, 2009, Pages 121-125

  Hashimoto, Yoshitaka ^a   Nago, Sachiko ^a   Tsunekawa, Masako ^a   Shibakawa, Kimio ^a   Miyata, Yasuyuki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

HPLC UV; Human blood; Landiolol; Metabolite; ONO 1101

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; LANDIOLOL;

ACCURACY; ARTICLE; CARDIOSELECTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; GENERAL ANESTHESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; QUALITY CONTROL; TACHYCARDIA; VOLUNTEER;

BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MORPHOLINES; QUALITY CONTROL; SPECTROPHOTOMETRY, ULTRAVIOLET; UREA;

EID: 59949086638     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.121     Document Type: Article

References (7)

1. Iguchi S., Iwamura H., Nishizaki M., Hayashi A., Senokuchi K., Kobashi K., Sakaki K., Hachiya K., Ichioka Y., Kawamura M., Chem. Pharm. Bull., 40, 1462-1469 (1992).
2. Tsunekawa K., Imawaka H., Yamamoto K., Shibakawa K., Hiraku S., Xenobiot. Metab. Dispos., 12, 31-41 (1997).
3. Nakashima M., Kanamura M., Iyaku Rinsho, 16, 1531-1556 (2000).
4. Guarracino F., Lapolla F., Cariello C., Danella A., Doroni L., Baldassarri R., Boldrini A., Volpe M. L., Minerva Anestesiol., 71, 335-337 (2005).
5. Murakami M., Furuie H., Matsuguma K., Wanibuchi A., Kikawa S., Irie S., Drug Metab. Pharmacokinet., 20, 337-344 (2005).
6. Takahata T., Yasui N., Sakamoto J., Suto K., Suto T., Tateishi T., Munakata A., Drugs R D, 6, 385-394 (2005).
7. "Guidance for Industry, Bioanalytical Method Validation," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S.A., 2001.